4.5 Article

Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions-A Consensus Document from the SAEM/HFSA Acute Heart Failure Working Group

期刊

ACADEMIC EMERGENCY MEDICINE
卷 22, 期 1, 页码 94-112

出版社

WILEY
DOI: 10.1111/acem.12538

关键词

-

资金

  1. NIH/NHLBI [K12HL1090]
  2. Medtronic
  3. Cardiorentis
  4. Abbott Point-of-Care
  5. Novartis
  6. Medicines Company
  7. Astellas
  8. Intersection Medical
  9. Radiometer
  10. Abbott Diagnostics
  11. Centers for Medicaid and Medicare Services (CMS)
  12. National Center for Advancing Translational Sciences [UL1TR000445]
  13. Roche Diagnostics
  14. National Institutes of Health
  15. European Union
  16. Health Resources Service Administration
  17. NIH
  18. Amgen
  19. Trevena
  20. Portola
  21. Siemens
  22. Mayday Foundation
  23. Pfizer
  24. NHLBI
  25. Sanofi Aventis
  26. Dyax
  27. Insys
  28. Novartis Pharmaceuticals
  29. Cardiorentis Inc.
  30. Trevena Inc.
  31. Mespere
  32. BG Medicine
  33. NIH/NIMHD [5 R01 MD005849-04]
  34. Alere
  35. Abbott
  36. Acorda Therapeutics Inc.
  37. Cardio3 Bioscience
  38. Cytokinetics
  39. Sorbent Therapeutics
  40. St. Jude

向作者/读者索取更多资源

Heart failure (HF) afflicts nearly 6 million Americans, resulting in 1million emergency department (ED) visits and over 1million annual hospital discharges. The majority of inpatient admissions originate in the ED; thus, it is crucial that emergency physicians and other providers involved in early management understand the latest developments in diagnostic testing, therapeutics, and alternatives to hospitalization. This article discusses contemporary ED management as well as the necessary next steps for ED-based acute HF research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据